Lexaria Bioscience Corp.
LEXX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348362
No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Lexaria Bioscience Corp. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 25 | 21 | −4 |
| Shares | 1.72M | 1.70M | −16.1K (−0.9%) |
| Value | $1.63M | $1.05M | −$581.6K (−35.6%) |
New holders (2)
Institutions that held Lexaria Bioscience Corp. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| MAI Capital Management | 200 | $124 | 0.00% |
| Morgan Stanley | 3 | $2 | 0.00% |
Sold out (6)
Institutions that held Lexaria Bioscience Corp. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Murchinson Ltd. | 419,590 | $399.7K |
| Wealth Enhancement Advisory Services, LLC | 35,776 | $29.9K |
| Virtu Financial LLC | 29,360 | $28.0K |
| Citigroup Inc | 429 | $409 |
| Rockefeller Capital Management L.P. | 200 | $191 |
| The PNC Financial Services Group, Inc. | 6 | $6 |